ArticleActa neuropathologica communications2024
Retinal peri-arteriolar versus peri-venular amyloidosis, hippocampal atrophy, and cognitive impairment: exploratory trial.
Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain-retina axis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Multimodal Retinal Imaging for the Detection of Early Alzheimer's Disease: Combining Biochemical, Structural, and Vascular Biomarkers.Bioengineering (Basel, Switzerland) · 2026Article
- Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sex-specific retina-brain signatures link ERα/ERβ imbalance with gliosis in Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Synergistic retinal UCHL1 dysregulation and synaptic vulnerability reflect Alzheimer's disease severity.bioRxiv : the preprint server for biology · 2026Article
- Identification of Chlamydia pneumoniae and NLRP3 inflammasome activation in Alzheimer's disease retina.Nature communications · 2026Article
- Cerebral Amyloid Deposition WithHuman brain mapping · 2025Article
- Non-Invasive Retinal Biomarkers for Early Diagnosis of Alzheimer's Disease.Biomedicines · 2025Review
- Color Fundus Photography and Deep Learning Applications in Alzheimer Disease.Mayo Clinic proceedings. Digital health · 2024Article
- Hyperspectral retinal imaging in Alzheimer's disease and age-related macular degeneration: a review.Acta neuropathologica communications · 2024Review
- Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024Review
- Dynamic retinal vessel analysis: flickering a light into the brain.Frontiers in aging neuroscience · 2024Review
- Retinal vascular biomarkers in mild cognitive impairment and Alzheimer's disease: a comprehensive review and meta-analysis.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
The relationship between amyloidosis and vasculature in cognitive impairment and Alzheimer's disease (AD) pathogenesis is increasingly acknowledged. We conducted a quantitative and topographic assessment of retinal perivascular amyloid plaque (AP) distribution in individuals with both normal and impaired cognition. Using a retrospective dataset of scanning laser ophthalmoscopy fluorescence images from twenty-eight subjects with varying cognitive states, we developed a novel image processing method to examine retinal peri-arteriolar and peri-venular curcumin-positive AP burden. We further correlated retinal perivascular amyloidosis with neuroimaging measures and neurocognitive scores. Our study unveiled that peri-arteriolar AP counts surpassed peri-venular counts throughout the entire cohort (P < 0.0001), irrespective of the primary, secondary, or tertiary vascular branch location, with a notable increase among cognitively impaired individuals. Moreover, secondary branch peri-venular AP count was elevated in the cognitively impaired (P < 0.01). Significantly, peri-venular AP count, particularly in secondary and tertiary venules, exhibited a strong correlation with clinical dementia rating, Montreal cognitive assessment score, hippocampal volume, and white matter hyperintensity count. In conclusion, our exploratory analysis detected greater peri-arteriolar versus peri-venular amyloidosis and a marked elevation of amyloid deposition in secondary branch peri-venular regions among cognitively impaired subjects. These findings underscore the potential feasibility of retinal perivascular amyloid imaging in predicting cognitive decline and AD progression. Larger longitudinal studies encompassing diverse populations and AD-biomarker confirmation are warranted to delineate the temporal-spatial dynamics of retinal perivascular amyloid deposition in cognitive impairment and the AD continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.